The MeAgain medical chief says she avoids compounded GLP-1s because no outcome data exists for them. She suggests asking whether the pharmacy has third-party quality certification.
Recap by typeshit. Full story at Yahoo Creators.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
Online sellers pitch peptides for weight loss, anti-aging and muscle gain, and Gavin Coote's full story looks at the risks of products nobody regulates.
The dermatology practice looks at why so many brands push peptides, and whether claims of firmer skin and fewer fine lines hold up.
He points to a 2025 otolaryngology study that tracked patients losing significant weight on GLP-1s and measured facial changes per 10 kg lost.
Loading…